Dewpoint Therapeutics
company
About
Dewpoint Therapeutics is a biotech company developing a drug platform that targets biomolecular condensates.
- 101 - 250
Details
- Last Funding Type
- Series C
- Last Funding Money Raised
- $150M
- Industries
- Biotechnology,Life Science,Medical,Therapeutics
- Founded date
- Jan 1, 2018
- Number Of Employee
- 101 - 250
- Operating Status
- Active
Dewpoint Therapeutics is a biotech company developing a drug platform that targets biomolecular condensates. Its technology uses machine-learning-based image analysis tools for visualizing condensates and offers an engine for genetically linked condensatopathy which is a collection of engineered cell lines with trackable condensates to prevent harmful protein sequestration, helping healthcare providers to have access to new therapies to address unmet needs.The company was founded in 2018 and is headquartered in Boston, Massachusetts.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$227M
Dewpoint Therapeutics has raised a total of
$227M
in funding over 2 rounds. Their latest funding was raised on
Feb 3, 2022 from a Series C round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Feb 3, 2022 | Series C | $150M | 2 | — | — | Detail |
| Sep 29, 2020 | Series B | $77M | 1 |
ARCH Venture Partners
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
2
Dewpoint Therapeutics is funded by 2 investors.
General Catalyst
and ARCH Venture Partners
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
General Catalyst
|
— | Series C |
|
ARCH Venture Partners
|
— | Series C |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
